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IT'S ONLY SKIN DEEP: FDA REGULATION OF
SKIN CARE COSMETICS CLAIMS
Bryan A. Liangt and Kurt M. Hartmantt
INTRODUCTION
Cosmetics have been used for thousands of years;' indeed, Phoeni-
cian and Egyptian women invented and used lipstick.2 Cosmetics, an
$18.5 billion industry,3 remain popular today with American consumers,
who spent $3.78 billion on retail skin care products alone in 1996.4 Reg-
ulation of cosmetics did not obtain modem statutory authority in the
United States until passage of the Food, Drug, and Cosmetic Act of 1938
(the "Act"). 5 This statute provided that certain cosmetics 6 were consid-
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1 See ALLm ED WARDEs & R. E. L. MASTERS, Tim CRADLE oF EROTICA 297-98 (1962).
2 See id.
3 See Jacqueline A. Greff, Regulation of Cosmetics That Are Also Drugs, 51 FooD &
DRUG LJ. 243, 243 (1996).
4 Across the major markets of Europe, facial skin care sales have grown by 25% since
1990 to $4.4 billion. Alpha-hydroxy acids have entered the mainstream, playing a significant
role in the growth of retail facial skin care sales in the US to almost $6 billion, with the market
continuing to increase by 8% a year.
Cosmeceuticals: Adding Value in a Changing Market, EuR. CosM. MA icars, May 1, 1996, at
197, available in LEXIS, Health Library, Curnws File.
U.S. retail sales of skincare products reached $3.78 billion in 1996, up from
$3.56 billion in 1995, according to Packaged Facts, a marketing research organiza-
tion. The market is projected to show steady increases, with retail sales reaching
$3.98 billion in 1997, $4.18 billion in 1998, $4.37 billion in 1999, and $4.57 billion
in 2000, notes packaged facts.
Roberta Gerry, Ironing Out Wrinkles, CsM~ucAL MARKET REPORTER, May 12, 1997, available
in 1997 WL 8496970.
5 21 U.S.C. §§ 321-362 (1992).
6 Cosmetics are defined in the Act as:
(1) articles intended to be rubbed, poured, sprinkled, or sprayed on, introduced
into, or otherwise applied to the human body or any part thereof for cleansing, beau-
tifying, promoting attractiveness, or altering the appearance, and (2) articles intended
for use as a component of any such articles; except that such term shall not include
soap.
21 U.S.C. § 321(I) (1992).
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ered to violate the Act if they were "deemed to be adulterated"7 or "mis-
branded."8 The Food and Drug Administration (the '"FDA") has been
delegated the authority to enforce the Act.9
Because the FDA has focused on physical safety of cosmetics in its
recent history,' 0 it has generally ignored unsubstantiated claims of effi-
cacy by cosmetics manufacturers, and has not attempted to prosecute
these products as per se misbranded under section 602 of the Act." In-
stead, the FDA, emphasizing its role as guardian of consumer safety, has
attempted to use its statutory powers to regulate cosmetics as drugs under
the definition in section 201(g)(1) of the Act. 12 To do this, the FDA
must establish that the cosmetic's "intended use" is as a drug.13 Once
deemed a drug, the cosmetic in question becomes subject to the extensive
requirements of new drug regulation, particularly pre-market approval
(including investigational new drug and new drug application proce-
dures), as well as drug labeling requirements. 14 If this drug status is
established in litigation, the FDA will usually obtain summary judgment
against the cosmetics manufacturer, since the material in question has
generally not been subjected to the rigorous new drug application and
approval process.
However, the FDA's focus on physical safety, and its attempted
designation of skin care cosmetics as drugs, has ignored the significant
responsibility of the agency to protect the public against highly question-
able efficacy claims by certain cosmetics manufacturers. The desire for
the agency to enter into this area should not be considered an idle wish;
the FDA is mandated by the Act to police cosmetics and act accordingly
"if [the cosmetic's] labeling is false or misleading in any particular."'5
Furthermore, because not all suits brought by the FDA in an attempt to
classify a purported cosmetic as a drug have been successful, it is impor-
7 21 U.S.C. § 361 (1992).
8 21 U.S.C. § 362 (1992).
9 Formal authority rests with the Secretary of Health and Human Services, see 21
U.S.C. § 371(a) (1992), who has, in turn, delegated the responsibility to the FDA.
10 See PrER BARTON Hunr & RicHARD A. MEmuuLL, FOOD AND DRUG LAW (1990)
(quoting George P. Larrick, Some Current Problems in the Regulation of Cosmetics Under the
Federal Food, Drug, and Cosmetic Act, 3 FOOD DRUG CosM. L.J. 570 (1948)).
11 See 21 U.S.C. § 362 (1992).
12 See 21 U.S.C. § 321(g)(1) (1992).
13 Under 21 U.S.C. § 321(g)(1), a "drug" is defined as (A) "articles recognized in the
official United States Pharmacopeia, official Homeopathic Pharmacopeia of the United States,
or official National formulary," (B) "articles intended for use in the diagnosis, cure, mitigation,
treatment, or prevention of disease," (C) "articles (other than food) intended to affect the struc-
ture or any function of the body," and (D) "articles intended for use as a component of any
articles specified in clause (A), (B), or (C)." Cosmetics are generally claimed to be drugs
under (B) or (C) when the FDA is attempting to regulate them as such.
14 See 21 U.S.C. §§ 321-362 (1992).
15 21 U.S.C. § 362(a) (1992) (emphasis added).
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tant to have an alternate strategy to protect the public against potentially
false cosmetics claims. Finally, subjecting cosmetic claims to more rig-
orous scrutiny under scientific peer review would result in a more in-
formed consumer who could make purchase decisions on the basis of
product quality rather than on the plethora of self-interested claims of
manufacturers.
Part I of this paper reviews the nature of the problem and the FDA's
litigation attempts to challenge misbranded traditional skin care cosmet-
ics. Part II discusses the FDA's regulatory methods, and considers the
efficacy and safety of various cosmeceuticals (products with both cos-
metic and pharmaceutical effects) in relation to their being marketed as
cosmetics or drugs, and also in relation to their respective advertisement
claims. Part III discusses policy considerations and proposes a method
for regulating cosmetics employing section 602 of the Act. Finally, this
paper concludes by calling for enhanced FDA regulation of cosmetics (as
mandated by the Act) to protect consumers from financial and physical
risks.
I. TRADITIONAL FDA CHALLENGES TO SKIN CARE
COSMETICS CLAIMS
The cosmetics industry has commonly made questionable claims in
its advertisements 16 and its labeling. 17 However, the lack of substantia-
tion of such claims has rarely been challenged as per se misbranding.
Perhaps because of early FDA failures in the courts when challenging
cosmetics as misbranded, 18 the FDA reevaluated its approach, changed
16 Note that the FDA and the Federal Trade Commission ("FTC") share responsibility in
regulating advertisements, with the FDA having primary jurisdiction over prescription drugs,
see 21 U.S.C. § 352(n) (1992), and vitamins and minerals, see 21 U.S.C. §§ 343(a)(2), 378
(1992), while the FTC regulates advertisements of over-the-counter drugs. See Hu-rr & MER-
RILL, supra note 10, at 599. However, since the claims in advertisements of the cosmetics
discussed here also appear on the package inserts and containers of the product, they are con-
sidered labeling and fall clearly within the FDA's jurisdictional authority under 321 U.S.C.
§ 362(a) (1992). Furthermore, the Supreme Court has held that a food product's advertise-
ments are considered labeling, and thus has sustained the FDA's contention that the food was a
drug based on advertisement claims: "[e]very labeling is in a sense an advertisement. The
advertising... here performs the same function as it would if it were on the article or on the
containers or wrappers. As we have said, physical attachment or contiguity is unnecessary
under § 201(m)(2) [21 U.S.C. § 321(m)(2)] [of the Act]." Kordel v. United States, 335 U.S.
345, 351 (1948). Courts have also held that concurrent FDA and FTC proceedings involving
the same or similar issues are acceptable and that statutory remedies from both agencies are
cumulative and not exclusive. See Warner-Lambert v. Federal Trade Commission, 361 F.
Supp. 948 (D.D.C. 1973).
17 See infra notes 48 and 165 and accompanying text.
18 In the first twenty years of the Act, there were 205 cosmetics notices of judgment;
seven of these were litigated. See James C. Munch & James C. Munch, Jr., Notices of Judg-
ment: Cosmetics, 14 FooD DRUG CosM. L.J 399, 401 (1958). Of these seven, two were
misbranding cases, and the FDA lost both. See id.
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its emphasis to the cosmetic-as-drug strategy, and focused on physical
safety. At least in the safety realm, there was potential for "blood on the
carpet,"'19 so as to bring the FDA's cases into more graphic relief for
courts and juries (and Congressional committees), and perhaps spur suc-
cess based partially on these images.20 Related to this consideration, the
FDA may have simply made a policy decision to divert its limited re-
sources21 to areas that have more public exposure, even in the wake of
recognition by the FDA itself that "cosmetic label claims... have be-
come more and more daring."'22
The recent history of skin care cosmetics challenges by the FDA
began with United States v. An Article... Consisting of 216 Individually
Cartoned Bottles, More or Less, of an Article Labeled In Part: Sudden
Change.23 In this classic case, the major issue was whether the FDA
could categorize the Sudden Change skin care product as a "drug" and
thus subject it to the extensive regulatory requirements for new drugs
(with which the manufacturer had not complied). The Sudden Change
court reversed the district court's ruling for the manufacturer. It held that
on the basis of the product's intended use and the relevant standard of a
consumer faced with such representations, Sudden Change was a drug.24
The court first noted that a product's intended use was to be deter-
mined on the "basis of its label, accompanying labeling, promotional ma-
terial, advertising and any other relevant source."25 The court also
emphasized that, regardless of the actual physical effect, a product will
be deemed a drug, for purposes of the Act, if the labeling and promo-
19 Personal communication from Peter Barton Hutt, Former Chief Counsel, Food and
Drug Administration; Partner, Covington & Burling, Washingon, D.C., to Bryan A. Liang,
June 1995.
20 Indeed, the Act was itself spurred into existence by tragedy: "a tragedy occurred
which was directly responsible for adding a new and important proviso to the drug control
legislation [the Act]. At least 73, perhaps over 90, persons ... died as a result of taking a drug
known as 'Elixir Sulfanilamide,' [d]iethylene glycol was used as a solvent." H-rr & MER-
RILL, supra note 10, at 476 (quoting David F. Cavers, The Food, Drug, and Cosmetic Act of
1938: Its Legislative History and Its Substantive Provisions, 6 LAW & CoNTEM. PRoBs. 2
(1939)).
21 The FDA, in 1986, devoted less than one percent of its budget to the regulation of
cosmetics. See Stephen H. McNamara, Performance Claims for Skin Care Cosmetics or How
Far May You Go in Claiming to Provide Youthfulness?, 41 FooD DRUG CosM. L.J. 151, 157
(1986). In 1994, the FDA has budgeted a similar percentage to cosmetics regulation (approxi-
mately five million dollars out of a total $80 million budget). See supra note 19.
22 McNamara, supra note 21, at 151-52 (quoting Arthur Hull Hayes, M.D., Commis-
sioner of Food and Drugs, statements to the Annual Meeting of the Cosmetics, Toiletry and
Fragrance Association, Boca Raton, Florida, March 2, 1983).
23 288 F. Supp. 29 (E.D.N.Y. 1968), rev'd 409 F.2d 734 (2d Cir. 1969).
24 See 409 F.2d at 742.
25 Id. at 739.
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tional claims indicate intended uses that bring it into the definition of a
drug.26
Next, the court indicated the appropriate consumer standard for use
in evaluating the claims made by skin care cosmetics manufacturers. Re-
jecting what it called the district court's "reasonable woman" standard,27
the Sudden Change court held that the relevant consumer standard is that
which includes "'the ignorant, the unthinking and the credulous,"' 28 and
thus the Act was intended to "protect unwary customers. ' 29 The court
related its accord with previous decisions in not allowing "those who
prey upon the weakness, gullibility, and superstition of human nature [to]
escape the consequences of their actions."30
The major claims of interest to the court were that Sudden Change
would "lift out puffs' 31 and give a "face lift without surgery. '32 These
claims were displayed on the product's leaflet insert, the box containing
the product, and advertisements in newspapers, magazines, store plac-
ards, and on television. The advertisements indicated that "[the product]
cannot eliminate wrinkles permanently. '33 Because these claims were
deemed by the court as having physiologic-i.e., drug connotations to
the court-constructed consumer, the court deemed Sudden Change a drug
under the definition in section 201(g)(1) of the Act,34 and it held for the
FDA.
In a similar case, United States v. An Article of Drug Consisting of
36 Boxes, More or Less, Each Containing One Bottle of an Article La-
beled In Part "Line Away Temporary Wrinkle Smoother, Coty, -35 a cir-
cuit court affirmed a lower court's ruling that a skin care cosmetic
product was a drug on the basis of its claims. Even though the leaflet
packaged with each box indicated that the effect of the cosmetic (like
Sudden Change) was only temporary, the court was disturbed by the de-
scriptions made by the manufacturer that Line Away was an "'amazing
protein lotion' . . . made in a 'pharmaceutical laboratory' and packaged
under 'biologically aseptic conditions."' 3 6 The court indicated that the
emphasis on protein content suggested that Line Away nourished the
26 See id.
27 See id. at 741.
28 Id. at 740 (quoting Florence Mfg. Co. v. J.C. Dowd & Co., 178 F. 73, 75 (2d Cir.
1910)).
29 Id. at 741 (quoting U.S. v. Cal's Tupelo Blossum U.S. Fancy Pure Honey, 344 F.2d
288, 289 (6th Cir. 1965)).
30 Id.
31 Id. at 738.
32 Id.
33 Id.
34 See 21 U.S.C. § 321(g)(1) (1992).
35 284 F. Supp. 107 (D.Del. 1968), aff'd, 415 F.2d 369 (3d Cir. 1969).
36 Id. at 372.
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skin. More disturbing to the court were the claims of aseptic manufac-
ture in a pharmaceutical laboratory, "imply[ing] that the product [was]
itself a pharmaceutical. ' 37 Furthermore, the Line Away court explicitly
noted that "puffery" is employed simply for the purpose of selling mer-
chandise.38 Thus, describing claims of the skin care product as such did
not make them de minimis. The court ultimately held that Line Away
was a drug for purposes of the Act.39
What appears to have triggered both courts in concluding that the
skin care cosmetics in the Sudden Change and Line Away cases were
drugs was the manufacturers' use and emphasis upon specific terms that
implied a physiologic effect and drug status. In Sudden Change, the
terms "face lift" and "surgery" were used strategically by the manufac-
turer to imply that use of the cosmetic would result in medical results
similar to plastic surgery. Similarly, in Line Away, use of the scientific
buzzwords "biologically aseptic" while being made in a "pharmaceutical
laboratory" simply led the court to believe that a consumer would imply
that the cosmetic was a scientifically formulated, therapeutic drug.40
Despite these successes, the FDA was not successful in using the
cosmetic-as-drug strategy in another skin care cosmetic case. In United
States v. An Article of Drug.. .47 Shipping Cartons, More or Less ....
"Helene Curtis Magic Secret,"4' the court held that the skin care prod-
uct, virtually identical in composition to both Line Away and Sudden
Change, did not constitute a drug on the basis of its intended use repre-
sentations. The court, in accord with the Sudden Change court, adopted
the standard of the "ignorant, unthinking, or credulous consumer,"42 and
the consideration of "whether the claim... constitute[s] a representation
that the product will affect the structure of the body in some medical- or
drug-type fashion"43 in ascertaining whether a cosmetic should be
deemed a drug.44 However, although the manufacturer made claims that
Magic Secret was a "pure protein"' 45 that caused an "astringent sensa-
tion,"46 the court held that the cosmetic was not a drug on the basis of its
claims, which were considered "less exaggerated" 47 than those reported
in Line Away and Sudden Change.
37 Id.
38 See id. at 741.
39 See id. at 742.
40 The Line Away court did not reach the question of the appropriate standard.
41 331 F. Supp. 912 (D.Md. 1971).
42 Id. at 917.
43 Id.
44 Id. (quoting Sudden Change, 409 F.2d at 741-42).
45 Id.
46 Id.
47 Id.
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Thus, the Magic Secret court introduced a tenuous "less exagger-
ated" standard to hold that the cosmetic's claim did not place it into the
feared drug category. This standard, in combination with the standards
promulgated in the Sudden Change and Line Away decisions, did not
significantly clarify the relevant lines over which a manufacturer cannot
step (or the FDA cannot validly challenge) in order to stay within the
safety of a cosmetics designation.
II. PUBLIC POLICY CONCERNS AND CONSIDERATIONS
A. MODERN REGULATORY METHODS
Almost thirty years ago, the Sudden Change and Line Away cases
revealed a general gray zone in which the courts supported the FDA's
attempts to denote a cosmetics manufacturer's claims broad enough to
place the product within the statutory drug category. The Magic Secret
court limited this ability somewhat by introducing an exaggeration con-
sideration. Presumably, claims that represented at least a "clear" exag-
geration by manufacturers on the order of Sudden Change or Line Away
would place their skin care products dangerously close to drug status.
However, as demonstrated by more recent labeling and advertise-
ments, the promise of relatively "unpuffed" claims by cosmetics manu-
facturers based on previous litigation has not been achieved. Indeed,
fifteen years after the Magic Secret case was decided, a cosmetics manu-
facturer, among others who made similar claims, put forth the following
skin care promotional claim:
[a]n unprecedented anti-aging complex ... helps con-
serve internal collagen . . . stop[s] age breakdown on
vulnerable areas . .. will actually diminish the length
and depth of wrinkles ... your personalized "prescrip-
tion" for vibrant, health-looking skin... helps relieve
and release puffiness... helps slow premature aging of
the skin . . . deep moisture penetration helps improve
skin texture and elasticity... actually helps prevent to-
morrow's lines from forming.48
Such claims, as compared to the thirty-year-old, almost naive-
sounding claims of the manufacturers in the Sudden Change, Line Away,
and Magic Secret cases, are arguably more "exaggerated" and use more
sophisticated scientific and medical terminology. To its credit, in 1987,
the FDA made some attempts to warn skin care cosmetics manufacturers
that claim that their products have anti-aging and anti-wrinkle properties.
48 McNamara, supra note 21, at 155-56 (quoting advertisements in CosMoporrAN,
GLAMouR, LADms' HoME JouRNAL, MADEMoISELLE, and VoGUE from the first half of 1985).
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No cases were brought to court; instead, in a series of regulatory letters
issued by the FDA to cosmetics manufacturers, the FDA indicated that it
considered "most of [the manufacturers'] anti-aging and skin physiology
claims... to be drug claims."'49 Thus, the FDA continued its cosmetic-
as-drug strategy in an attempt to control questionable cosmetics claims
by manufacturers.
This regulatory process is inefficient for both the FDA and cosmet-
ics manufacturers and does not appear to have stemmed the tide of ques-
tionable cosmetics claims.50 The regulatory letter process was outlined
in Est'ee Lauder, Inc. v. U.S. Food & Drug Administration,51 where a
cosmetics manufacturer attempted to obtain clarification of cosmetic
claims that would deem its product a drug. The regulatory letter process
was described in the case as follows, with a focus upon the interplay
between the FDA and Est'ee Lauder:52
1. In early 1987, the Director of the FDA Office of Compliance for
the Center for Drugs and Biologics ("Director") issued to more than 20
cosmetics manufacturers and distributors regulatory letters that indicated
its objection to certain product claims during marketing of anti-aging and
anti-wrinkle creams. On April 17, 1987, the Director wrote Est'ee
Lauder objecting to some of its claims. The letters contained a review of
current labeling for the product and claims that the Director believed to
be drug claims. The Director asked that the company take "prompt" ac-
tion to correct enumerated violations and warned Est'ee Lauder that the
FDA was prepared to invoke sanctions such as seizures or injunctions
under the Act; he then asked Est'ee Lauder to advise the FDA of the
firm's actions.
2. In response to the Director's letter, twelve companies wrote and
later met with the FDA in May and July, 1987.
3. On the basis of these meetings, the twelve companies formed a
coalition and sent John M. Taylor, FDA's Associate Commissioner for
Regulatory Affairs, a proposal which attempted to devise a framework
for distinguishing between cosmetic and drug categories.
4. On November 18, 1987, Taylor advised firms that he did not
agree with their proposal, particularly for the skin care anti-wrinkle and
anti-aging claims. He requested the firms to respond within 30 days re-
garding measures that they would take to correct the objectionable claims
identified in the regulatory letters.
49 HTr & MERuLL, supra note 10, at 829 (quoting the FDA's Associate Commissioner
of Regulatory Affairs response to cosmetics industry coalition).
50 See infra note 165 and accompanying text.
51 727 F. Supp. 1 (D.D.C. 1989).
52 See id. at 3-4.
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5. After many letters, phone conversation, and meetings, Est'ee
Lauder submitted a proposal to FDA for revising its skin products'
claims on December 18, 1987.
6. On March 24, 1988, Taylor responded to Est'ee Lauder's propo-
sal, indicating his belief that the company's labeling still violated the
Act.
7. Four days later, counsel for Est'ee Lauder met with another FDA
official requesting guidelines for industry assistance. Est'ee Lauder fol-
lowed up this meeting with a letter dated May 4, 1988, indicating that the
company was eliminating older promotional materials.
8. One month later, an FDA official from the Office of Compliance
wrote back to Est'ee Lauder, notifying the company that its response to
the regulatory letter did not bring its products into compliance with the
Act for its skin care products and since it had not submitted any exam-
ples of its revised labeling to the FDA.
9. On July 12, 1988, Est'ee Lauder submitted proposed revised la-
beling for the skin care products in question referred to in the April 17,
1987 regulatory letter.
10. In a letter dated September 2, 1988, the Director indicated that
some of the revised labeling continued to be objectionable due to skin
care claims and requested that the claims be removed. He requested that
if Est'ee Lauder was not willing to make the changes identified, it should
indicate such to the FDA within ten days.
11. On September 13, 1988, Est'ee Lauder stated it would contact
the Director "as soon as possible."
12. On September 23, 1988, Est'ee Lauder filed suit against the
FDA in U.S. District Court.
13. On June 16, 1989, the case was dismissed by the court.53
The Est'ee Lauder case took the FDA, Est'ee Lauder and regulatory
observers on an almost two-and-a-half year circular journey that accom-
plished nothing-neither FDA approval for Est'ee Lauder's claims, nor
termination of use of offensive labeling by Est'ee Lauder for at least this
time period. Further, no clarification was made as to how claims could
be brought into compliance with the Act from the cosmetics manufac-
turer's point of view, although both parties expended significant re-
sources in their respective efforts. Thus, the Est'ee Lauder case
illustrates the fundamental need for additional, more efficient strategies
for the FDA to police cosmetics claims, as well as provide cosmetics
53 Id. The case was dismissed by the court because the regulatory position taken by the
FDA did not constitute the agency's final position, and thus the case was not ripe for judicial
review. See id. at 6.
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manufacturers with a clear sense of what is expected of them in their
labeling and advertisements.
B. MOVING INTO THE MODERN AGE: COSMETICS OR DRUGS?
Although the cosmetic industry in the United States is an $18.5 bil-
lion industry, "[c]osmetics are the only major FDA-regulated product
group that does not have its own center within the FDA."54 Unfortu-
nately for American consumers, the relative lack of attention given to
cosmetics regulation by the FDA 55 has resulted in more potent (i.e., more
dangerous) materials being sold. These products have slipped through
the cracks at the FDA because they have avoided the FDA's stringent
drug approval process and have passed directly to consumers via the re-
tail cosmetics shelf. Indeed, as cosmetics, these products have entered
the market without information as to safety precautions, adverse side-
effects, or efficacy. However, the stakes are higher here; since these
products can also cause physical harm in addition to economic harm, it is
even more imperative that the FDA exercise some authority over assess-
ing whether these products should be on the market. The following sec-
tions will discuss products that should either be regulated as drugs
generally or as drugs at certain concentrations; as well, these should also
be more heavily regulated under section 602 of the Act. In addition, to
contrast the questionable retail products to be discussed, the FDA-ap-
proved drug, Renova, will be discussed to illustrate a model approval
process that all drug-effect cosmetics should undergo.
1. Topical Aminophylline
Just as the new g~neration of anti-aging cosmetics have caught the
attention of consumers in search of young new skin, aminophylline 56 "fat
reducing" creams have caught the attention of women in search of thin-
ner thighs.5 7 Like most cosmetics, topical aminophylline creams have
escaped the FDA drug approval process by being marketed simply as
cosmetics without any supporting data.58 As far as efficacy claims are
54 Greff, supra note 3, at 248.
55 In 1997, President Clinton signed into law the Food & Drug Administration Moderni-
zation Act ("FDAMA"), which amended the Food, Drug, and Cosmetic Act to streamline and
rationalize the new drug and medical device approval process; however, it did not address the
issues surrounding the misbranding or safety concerns of cosmetics. See Pub. L. No. 105-115,
111 Stat. 2296 (1997).
56 Aminophylline is a prescription drug for asthma when taken internally. See Thin
thighs in a bottle!?; fat dissolving-creams, THE UNIvERsrrY OF CALwORNIA, BERKELEY WELL-
rNmss LmEimR, June 1994, at 1, available in LEXIS, Health Library, Allnws File.
57 In just over one year from the release of patented topical aminophylline cream, over
15,000 women had purchased the product. See Pamela A. Simon et al., Skin reactions to
topical aminophylline, 273 JAMA 1737 (1995).
58 See Thin thighs in a bottle!?; fat dissolving-creams, supra note 56.
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concerned, few relevant, neutral studies have been published. The patent
for this cosmetic was granted based upon an experiment using only five
obese women who were injected with the drug in the thighs and who
were concurrently following a 1,200 calorie-a-day diet program.5 9 The
experiment was considered "hardly impressive,"60 since the product is
being sold as a topical cosmetic cream and not as an intra-muscular in-
jection. Furthermore, there is no evidence that aminophylline would
work as a cream if applied to humans. Claims by the holders of the
patent that eleven women who had rubbed their thighs with two-percent
aminophylline cream for a period of six weeks had seen a reduction in
thigh circumference by about 0.5 inches,61 were attributable, according
to an academic endocrinologist, to temporary water loss.62
Marketing for aminophylline-containing products is typically out-
landish. For example, an advertisement for "Liposlim," an aminophyl-
line containing "contouring gel," claims: "Liposlim is a deeply-
penetrating body contouring gel.... Use it to lose inches off your thighs,
hips, abdomen, buttocks, and chin."'63 Although the above product
claims to work on other areas of the body besides the thigh area,64 the
patented cream65 is normally marketed as a "thigh smoother," and not as
an actual "fat reducer," so as to "avoid potentially embarrassing confron-
tations with the FDA. '66
There are several product sellers in the market, including Smooth
Contours, Thermojetics, and Skinny Dip, that are currently licensed to
use the cream. The cream costs approximately thirty to forty dollars for
a two-week supply and requires constant application in order to prevent
the loss of any perceived benefit.67 Thus, a woman who uses one of
these products for twenty-five years could spend as much as $240,000 to
receive a negligible benefit that could cause serious harm.68
59 See id.
60 Id.
61 See E.C. Hamilton et al., Regional Fat Loss from the Thigh Using Topical 2% Ami-
nophylline Cream, 1 0BEsrrY REs. 95S (1993).
62 See Katherine Griffin, A thigh-slimming cream that works?, HimTH, March 1994, at
36, available in LEXIS, Health Library, Alnws File.
63 ALLURE, March 1997, at 162.
64 See id,
65 According to Bray and Greenway, the aminophylline cream penetrates the skin
to reach the layer of fat cells below, where it triggers a series of chemical changes.
They believe the causes fat molecules inside the cells to break down into fatty acids,
which then slip past the cell membrane and into the bloodstream.
Griffin, supra note 62, at 36.
66 Thin thighs in a bottle!?; fat dissolving-creams, supra note 56, at 1.
67 See Id.
68 See id. Higher levels of fatty acids in the blood stream could be extremely dangerous.
See Griffin, supra note 62, at 36; infra note 73 and accompanying text (reviewing the safety
problems of aminophylline).
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Ironically, if aminophylline cream actually does shrink fat cells as
claimed, there could be major trouble with the FDA for marketing a cos-
metic product that provides a drug-like reaction.69 The fact that ami-
nophylline-containing products have already boasted that their product
"deeply penetrates" the skin should be enough to send up a red flag to the
FDA that this is a drug with unknown safety hazards. Furthermore, since
the product is marketed as a harmless cosmetic, unwary consumers, who
are more likely to be concerned with losing fat than with whether or not
the product should rightfully be subjected to the drug approval process
by the FDA, may abuse the product on the assumption that it is com-
pletely safe. As one prospective purchaser said in a fax sent to Dr. Bruce
Frome, who is involved in licensing the cream, "I really don't think peo-
ple care if this product has side effects. Women will do just about any-
thing for thinner thighs."'70
Beyond the lack of efficacy data, safety issues surrounding topical
aminophylline have raised concerns from some researchers who believe
that there may be possible long-term danger associated with "circulating
aminophylline," if it is in fact absorbed into the skin.71 Furthermore,
"some researchers fear that any fat released from cells in one area may
circulate in the bloodstream and ultimately be deposited elsewhere in the
body-perhaps even in the coronary arteries. '72 At least one adverse
side-effect, topical dermatitis, has been reported in some users.73 As
stated in the Journal of the American Medical Association, "topical der-
matitis is due to a type IV hypersensitivity reaction to the
ethylenediamine complexed in the aminophylline molecule." 74 In addi-
tion, physicians are likely to see cases of contact dermatitis resulting
from the ethylenediamine in the aminophylline molecule, and indeed,
"practitioners may still report adverse skin reactions associated with
these [aminophylline] creams to the FDA Medical Products Reporting
Program MedWatch at (800) FDA-1088 ' '75 -a hotline used for adverse
drug reactions-despite the fact that the creams are classified as cosmet-
ics and not drugs. 76
It thus appears that aminophylline cream runs afoul of the Act, both
in product claims and actual physiological effect. Moreover, the fact that
69 Griffin, supra note 62, at 36.
70 Id.
71 Peg Jordan, Learn to scrutinize claims; when choosing cosmetics and fitness tech-
niques, AMERICAN FrrNuss, Sept. 1994, at 6, available in LEXIS, Health Library, Allnws File.
72 On your mind; A thigh-thinning cream?, CONSUMmR REP. ON H ALT, Sept. 1994, at
108, available in LEXIS, Health Library, Allnws File.
73 See Simon et al., supra note 57, at 1737.
74 Id.
75 IL
76 See id.
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there has been great concern over topical aminophylline's safety, coupled
with the lack of published data on its safety profile, is cause enough to
demand FDA intervention. However, by carefully wording the product's
advertisements, sellers are able to hide in the gray area between cosmet-
ics and drugs that the FDA has yet to directly attack, although presently
the FDA is "evaluating" whether thigh creams should undergo drug ap-
proval in an effort to better protect the public health.77
2. A New Wrinkle: Cosmeceuticals
As implied by the name, the term cosmeceutical is a hybrid of the
terms cosmetic and pharmaceutical.78 Many cosmeceuticals are simply
pharmaceuticals that have either been re-formulated for consumer use
(i.e., use a lower concentration of the "active ingredient") or have long
been approved for non-cosmetic use.
The cosmetic consumer is continually in search of products that will
cease, and even reverse, the aging process of the skin (i.e., wrinkling).7 9
Wrinkles appear as a result of the elastic fibers of the dermis (the layer of
tissue beneath the epidermis) deteriorating from aging, and in most cases,
as a result of damage caused by the sun's ultraviolet rays.80 The deterio-
ration process starts when there is an excessive production of abnormally
structured elastic fibers.8 ' Under normal circumstances, the excessive
deterioration is not noticeable until after age seventy; however, sun-dam-
aged skin may show signs of excessive deterioration as early as age
thirty.
8 2
Skin care cosmetics are essentially defined as "products which are
limited to temporary improvement of the appearance or feel of the
skin.' 8 3 Traditional cosmetic moisturizers do nothing more than tempo-
77 Thigh Creams, CFSAN, FDA, OFFICE OF COSM. FACr SHEr, Feb. 22, 1995, (visited
May 7, 1998) <http://vm.cfsan.fda.gov/-dms/cos-202.hml>.
78 See Still Pushing Back the Boundaries of C&T, Eui. CosM. MARKErs, May 1995,
available in LEXIS, Health Library, Allnws File.
79 See supra note 4 (discussing the billion dollar market for anti-wrinkle cosmetics such
as alpha hydroxy acids).
80 In the aging process there are changes in the connective tissue that are subtle and not
easily detected until a secondary manifestation appears. Such is the case in the vascular sys-
tem where blood vessels are slowly altered owing to elastin degradation or modification....
Elastin provides a return spring system for the skin, allowing the collagen fibers to return to
their original position after deformation.
Peter T. Pugliese, Assessment of Antiaging Products, in CLINCAL SAFETY AND EFFICACY
TEsTnNG OF Cosaa-ncs 298-99 (William C. Waggoner, ed., 1990).
81 See Dori Stehlin, Erasing Wrinkles: Easier Said Than Done, FDA CONSUMER, July
1987, at 20, available in LEXIS, Health Library, Allnws File.
82 See id.
83 Robert L. Goldemberg, Believe It or Not; Cosmetics, Pharmaceuticals Often Bear
Questionable Marketing Claims, DRUG & CosM. INDus., March 1997, at 64, available in
LEXIS, Health Library, Cumws File.
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rarily keep water from evaporating on the skin's surface cells. The result
is that moisturized skin, even skin that already has noticeable wrinkles
from aging or sun exposure, takes on a softer and smoother appearance
with greater "flexibility."'8 4 Products that are known to have an actual
physiological effect (i.e., products that alter the structure of the skin) and/
or make claims akin to having an actual physiological effect (e.g., claims
to make skin "function as if it were young again"85 ), may be considered a
drug for regulatory purposes, according to FDA guidelines.8 6 There is,
however, a gray area between the strictly-defined cosmetic and the
strictly-defined drug. The products that fall within this gray area have
been termed cosmeceuticals.87
Cosmeceuticals are products that claim to have an actual physiolog-
ical effect,8 8 which is usually not scientifically substantiated, 89 and is
temporary in nature because the claimed effect is dependent upon contin-
ued and frequent use of the product. Cosmeceuticals are a fairly new
generation of products that have sparked FDA attention as a result of
marketing "claims creep." 90 Many cosmetics manufacturers have made
both aggressive and inventive claims about the physiological benefits de-
rived from their products-claims which bring them close to, if not well
within, the drug category.91 Moreover, because of the significantly dif-
ferent labeling requirements for cosmetics versus drugs,92 those cos-
meceuticals that rightfully should go through the FDA's drug approval
84 See Stehlin, supra note 81, at 20.
85 Id.
86 See id.
87 See Cosmeceuticals Bridging the Health / Beauty Divide, OTC NEws & MARKEr
RFn., June I, 1997, at § 104, available in 1997 WL 8740585.
88 "Cosmetic claims are a type of pre-emptive claim which associate product usage with
some desirable physiological skin change such as the elimination of wrinkles. Some cos-
meceutical product claims are not adequately substantiated using scientific methodology, but
depend upon testimonials from celebrities as evidence of efficacy." Thomas 3. Stephens et al.,
Assessment ofAntiaging Products, in CLNICAL SAP=Y AND EFFCACY TEST rG OF CosMETIcs
3-5 (William C. Waggoner ed., 1990).
89 "True 'antiaging' actions would require evidence for the return toward normal of the
regenerative/ degenerative balance by increased collagen and elastin synthesis." Charles Fox,
Topical Bioactive Materials; part 2, CosM. & TomIERms, Sept. 1994, at 83, available in
LEXIS, Health Library, Arcnws File.
90 Stephen H. McNamara, FDA Regulation of Cosmeceuticals: U.S. Cosmetic and Drug
Regulations Pertinent to the Cosmeceutical Issue, CosM. & Ton.Erlins, March 1, 1997, at 41,
available in 1997 WL 10053046.
91 See id.
92
Generally, the label on a cosmetic is required to list all ingredients in descend-
ing order of predominance, while the label on a drug is required only to list its
'active' ingredients. If an article is both a cosmetic and a drug, it must list the active
ingredients first, followed by other ingredients in descending order of predominance.
(The FDA also generally encourages the voluntary listing of inactive ingredients on
the labels of OTC drugs.)
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process93 (because they do in fact have an actual physiological effect on
the skin), are posing a serious threat to unwary consumers.
The FDA has done relatively little to address these claims specifi-
cally and the cosmeceutical movement in general. As a result, a compet-
itive environment among cosmetics manufacturers has developed
whereby all cosmetics manufacturers are forced to meet their competi-
tors' increasingly grandiose product claims with similar claims of their
own. For a cosmetic company to stay silent or limit its claims to what
can be proven would place that company at an economic disadvantage;
consumers are likely to buy the "most potent" retail skin care cosmetic
product, as defined by product advertising. Thus, until the FDA does
step in to regulate cosmeceuticals, it is economically beneficial for all
cosmetics manufacturers to aggressively promote and market these gray
area products. Moreover, until the FDA does take appropriate regulatory
action, whether under section 602 or under its drug regulatory power, it
is the consumer who must bear the burden of assessing the truth or falsity
of these products' claims. Of course, these are the very individuals who
lack expertise in the area and thus may be misled by the overstated and
ever increasing fraudulent claims.
3. Retinoids
An example of a product that has been re-marketed for wrinkle re-
duction as an alternative use is Johnson & Johnson's Retin-A (a deriva-
tive of tretinoin), a product long used for the treatment of severe acne.94
Retin-A had the side-effect of "reducing visible lines in the skin," 95 a
side-effect that would be welcomed by any skin care cosmetic consumer.
To be sure, during the year that Retin-A's wrinkle-reducing side-effect
was publicized, sales of the product in the United States rose by 340%
from $25 million to $110 million.96 Unfortunately for Johnson & John-
son, however, it violated FDA rules and promoted Retin-A for an unau-
thorized use, and it was consequently fined $5 million and forced to pay
another $2.5 million in restitution for government expenses. 97 Neverthe-
less, the decision to promote Retin-A for a use other than what had been
FDA-approved remained economically cost effective despite the $7.5
million total fine levied against Johnson & Johnson, as the company still
profited enormously from sales of the product. Thus, even when the
FDA has taken action, the action still has not effectively monitored the
93 Most cosmetic drugs conform to over-the-counter drug monograph requirements,
thereby avoiding the drug approval process. See Greff, supra note 3, at 243.
94 See Still Pushing Back the Boundaries of C&T, supra note 78.
95 Id.
96 See Cosmeceuticals: Adding Value in a Changing Market, supra note 4, at 197.
97 See Phantom Competitor, CosM. INsRas' REP., Apr. 24, 1995, at § 8, available in
LEXIS, Health Library, HCare File.
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safety and use of these products, and it certainly has not deterred manu-
facturers from selling the product when these companies have deemed a
profit might still be made.
Furthermore, other similar products have been able to make unsub-
stantiated claims with seeming impunity. Take, for example, Lancome's
magazine advertisement for its "Renergie" skin care product: "Double
performance anti-wrinkle and firming treatment scientifically proven in
its dual ability to firm and strengthen skin while diminishing the appear-
ance of wrinkles. Fortified with proteins and age-defiant elements. For
face and throat, in a choice of silky creme or new oil-free lotion."98
Although the advertisement claims that its product's beneficial ef-
fect has been "scientifically proven," the advertisement cites no study,
provides no information substantiating the claimed efficacy and safety of
the product, and lists no ingredients. Furthermore, the use of the term
"age defiant" implies a cessation of the aging process-a claim that ar-
guably constitutes a section 602 violation.
Similarly, Neutrogena boasts, in a magazine advertisement, that its
Healthy Skin Anti Wrinkle Cream is "dermatologist recommended" and
"clinically proven:"
Visibly reduce the appearance of fine lines and wrinkles
from sun damage. In days, skin is softer, smoother. In
weeks, the appearance of fine lines, wrinkles and age
spots diminish. Your skin looks firmer, younger, health-
ier. Clinically proven formula with Retinol (the purest
form of Vitamin A) works deep within the skin's surface
where wrinkles develop. Contains Pro-Vitamin B5, Vi-
tamin E and special moisturizers for softer, smoother
skin.9 9
Although this Neutrogena advertisement does list certain key ingre-
dients, it does not disclose the concentration of the retinoid used, it
claims a "clinically proven" result, and it blatantly implies that the prod-
uct penetrates the skin by stating that it "works deep within the skin's
surface."' 100 Also, while the advertisement is designed to lead the con-
sumer to believe that the product will actually penetrate the skin by stat-
ing that it "works deep within,"'1 1 the advertisement is carefully worded
to avoid being considered (technically) to have a drug effect by qualify-
ing the degree of penetration as affecting only the "skin's surface."' 10 2
98 ALLURE, Mar. 1997, at 71 (emphasis added).
99 REDBOOK, Apr. 1998, at 13.
100 Id.
101 Id.
102 Id.
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The FDA has demonstrated concern that the ingredients in these
new cosmeceuticals (which have been shown to cause irritation), even if
naturally occurring, "might be stripping the skin of its natural protective
barriers."10 3 Dr. Zoe Draelos, Clinical Assistant Professor of Dermatol-
ogy at Wake Forest University, commented on the issue of irritation
caused by anti-aging products by stating, "when skin stings and bums,
it's telling you that it's injured .... Perhaps, instead of the anti-aging
benefits, we're actually injuring the skin."'104 Yet even under these phys-
ical harm concerns, no regulatory action has been taken. And like most
cosmetic advertisements, although cosmeceutical advertisements state
that their products are "clinically proven," they fail to cite any peer-re-
viewed studies attesting to efficacy or safety. These factors would thus
seem to indicate that the FDA should reconsider its current efforts to
regulate these cosmetics.
4. Alpha Hydroxy Acids
Alpha hydroxy acids (AHAs) s05 also represent a crossover between
cosmetics and drugs. The typical effects of alpha hydroxy acids have
been described as follows:
Alpha hydroxy acids are basically chemical versions of
facial scrubs. When applied topically, they slough off
the dead cells of the skin's top layer, forcing the under-
lying cells to create fresh new cells to replace them. The
body may also attempt to repair this minor "damage" by
depositing new collagen in the underlying, dermal layer.
103 Lisa Kintish, Treatment Cosmetics: Beyond the Surface; Companies Develop Makeup
With Added Benefits for the Skin, SOAP-CosM.-CHEMICAL SPECIALTmS, Mar. 1997, at 26,
available in LEXIS, Health Library, Curnws File; Laura A. Heymann, The Cosmetic/Drug
Dilemma: FDA Regulation of Alpha-Hydroxy Acids, 52 FOOD & DRUG L.J. 375, 375 n.129
(1997) (citing Jacqueline A. Greff, Regulation of Cosmetics That Are Also Drugs, 51 FOOD &
DRuG LJ. 243, 257 (1996) (quoting John E. Baily, Jr., Ph.D., Acting Dir., Office of Cosmetics
& Colors, FDA, Skin Care B State of the Art: A Regulatory View of B Alpha- Hydroxy Acid,
Remarks at the Annual Spring Seminar of the New York Chapter of the Society of Cosmetic
Chemists, New York City, Apr. 6, 1994)).
104 Fighting Time: With Its Patented Beta Hydroxy Complex, Oil of Olay Age Defying
Series Dawns On A New Age In Skin Care, SoAP-CosM.-CimMIcAL SPECIALTIm, May 1997, at
66, available in LEXIS, Health Library, Curnws File.
105 Alpha hydroxy ingredients include glycolic acid, lactic acid, malic acid, citric acid,
glycolic acid plus ammonium glycolate, alpha-hydroxyethanoic acid plus ammonium alpha-
hydroxyethanoate, alpha-hydroxyoctanoic acid, alpha-hydroxycaprylic acid, hydroxycaprylic
acid, mixed fruit acid, tri-alpha hydroxy fruit acids, triple fruit acid, sugar cane extract, alpha
hydroxy and botanical complex, L-alpha hydroxy acid, and glycomer in crosslinked fatty acids
alpha nutrium (three AHAs). See Alpha Hydroxy Acids in Cosmetics, FDA BACKGROuNDER,
FDA, July 3, 1997 (visited May 7, 1998) <http://vm.cfsan.fda.gov/ -dms/cos-aha.htm>.
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The result is smoother, firmer, more evenly pigmented
skin.106
The AHA is an example of a drug that has long been used, at high
concentrations, for controlled chemical peels in a physician's office, and
that has made the transition to the over-the-counter retail cosmetic mar-
ket with concentrations that are greatly reduced, yet arguably effec-
tive. 10 7 AHAs come in different concentrations and different pH levels.
The concentration of the product will determine its effect on the dermal
layer of the skin, and the effects range from light peeling to complete
resurfacing and scarring. Dermatologists have used AHAs during in-of-
fice treatments with twenty to seventy percent concentrations, while re-
tail AHA products utilize two to twelve percent solutions. 10 8 In addition
to concentrations, the actual absorption of an AHA into the skin will
depend critically on the formulation's pH level, with optimal absorption
of the AHA into the skin at a pH of 3.0.109
Cosmetics manufacturers have experimented with products that
have a borderline drug concentration of AHAs. The marketing strategy
of retail AHA cosmetics manufacturers is to keep the concentrations of
their products low enough to avoid falling into a drug category and,
therefore, becoming subject to drug regulations, while simultaneously
keeping their concentrations high enough to have an actual effect, or at
least be able to claim an effect. 110 If, however, the concentration is in
fact too low, the result is that consumers pay a exorbitant price for what
is essentially a moisturizer with the same effect as petroleum jelly."'
Most AHA product advertisements, unfortunately, do not inform the con-
sumer as to the product's concentration or pH levels. For example,
Avon's magazine advertisement for its "A New All-in-One" reads as fol-
106 Mary Roach, Heavenly Skin, HEALTH, July 1986, at 94, dvailable in LEXIS, Health
Library, Allnws File.
107 Routine use of skin-care cosmetics with alpha-hydroxy acids ("AHAs") moisturizes
and smoothes the skin providing a less wrinkled skin appearance. See Donald G. Vidt &
Wilma F. Bergfeld, Cosmetic use of alpha-hydroxy acids, 64 CLEVELAND CLDUCAL J. MED.
327 (1997).
108 See Roach, supra note 106, at 94.
109 See Anne Wolven Garrett, AHAs and More; Alpha Hydroxy Acids Discussed At Soci-
ety of Cosmetic Chemists Annual Meeting; Scientifically Speaking, DRUG & COSM. INDUS.,
Jan. 1997, at 8, available in LEXIS, Health Library, Curnws File.
110 Because an AHA containing a product's effectiveness is dependent upon its concentra-
tion and pH level, "[o]ne concern is that absent regulation, manufacturers will attempt a race to
the top, increasing concentration of the acid in their products to achieve a more drastic effect"
Laura A. Heymann, The Cosmetic/Drug Dilemma: FDA Regulation of Alpha-Hydroxy Acids,
52 FooD & DRUG L.J. 357, 359 (1997).
111 "Moisturizers form a seal that keeps water from evaporating from the skin's surface
cells. More water in the cells means greater flexibility, softness, and smoothness. This effect
can come with equal success from a $65 bottle or exotically named cream or a plain jar of
petroleum jelly." Stehlin, supra note 81, at 20.
1999] COSMEICS CLAIMS
lows: "Give your skin a second chance with one alpha hydroxy formula
that smooths, moisturizes and protects. Now with SPF 15 and antioxi-
dants. See younger looking skin in two weeks or your money back.
Guaranteed." 112
Yet, irrespective of the safety1 3 and efficacy issues surrounding
AHAs and their varying concentrations, as of 1997, AHA products had
reached one billion dollars in sales worldwide." 4 Presently, the FDA
has not taken any regulatory or legal action against cosmetics manufac-
turers of AHAs, although these products clearly have the potential of
causing both economic and physical harm. This inaction on the part of
the FDA is indefensible, in light of the fact that the FDA has itself pub-
lished concerns about potential skin irritation caused by use of AHAs,
and it has received at least 100 reports" 5 citing adverse effects "ranging
from mild irritation and stinging to blistering and bums." 6
In addition, although the majority of the literature assessing AHAs
finds that topical AHAs are effective in some instances," 7 a study per-
formed by the Cosmetic Ingredient Review (CIR) 1 8 found that there was
112 ALLURE, Mar. 1997, at 107.
113 See Eric F. Bernstein et al., Citric Acid Increases Viable Epidermal Thickness and
Glycosaminoglycan, 23 DERmATOLOGICAL SURGERY 689 (1997).
114 See Symposium: Skin Disorders, 102 POSTGRADUATE MED. 115 (1997), available in
1997 WL 9104705.
115 "Past experience suggests that for every adverse reaction report the agency receives,
the manufacturer receives 50 to 100." Paula Kurtzweil, Alpha Hydroxy Acids For Skin Care:
Smooth Sailing or Rough Seas?, FDA CONSUNR, FDA, Mar.-Apr. 1998 (visited May 7, 1998)
<http:/vm.cfsan.fda.gov/-dms/fdacaha.htnl>.
116 Alpha Hydroxy Acids in Cosmetics, supra note 105.
117 In one double-blind study, it was concluded that AHAs had "modest but real benefits"
when applied to women with mild to moderate photoaging. See Matthew J. Siller et al., Topi-
cal 8% Glycolic Acid and 8% Lactic Acid Creams for the Treatment of Photodamaged Skin,
132 ARcHIVEs OF DERMATOLOGY 631, 632 (1996). In a second study, "[tiest participants
applied either 5% or 12% lactic acid twice a day for 3 months. Changes in skin smoothness
and texture, the depth and number of lines and wrinkles, and epidermal and dermal firmness
and thickness were determined." Walter P. Smith, Epidermal and Dermal Effects of Topical
Lactic Acid, 35 J. AM. ACAD. DERmTOLOGY 388, 388 (1996). The results of the study were
as follows: "Treatment with 12% lactic acid resulted in increased epidermal and dermal firm-
ness and thickness and clinical improvement in skin smoothness and in the appearance of lines
and wrinkles. No dermal changes were observed after treatment with 5% lactic acid; however,
similar clinical and epidermal changes were noted." Id. The study concluded that "cosmetic
benefits from the use of a-hydroxy acids are caused by modification of the skin surface, the
epidermis and the dermis." Id.; see also Barbara A. Gilchrest, A Reviev of Skin Aging and Its
Medical Therapy, 135 BRrrSH J. DERMATOLOGY 867 (1996).
118 The CIR consists of a seven-member independent expert panel selected through
a public nomination process from among the scientific disciplines of dermatology,
pharmacology, chemistry, and toxicology. Three nonvoting members assist the
panel: a consumer representative appointed by the Consumer Federation of America,
an industry liaison, and an FDA contact person. The CIR reviews both published
and unpublished industry data. The panel classifies ingredients as either safe, as
currently used or with qualifications; unsafe; or insufficient information for a deter-
mination. CIR findings are reported to members of the industry in the annual CIR
268 CORNELL JOURNAL OF LAW AND PUBLIC POLICY [Vol. 8:249
insufficient evidence to ascertain a clear benefit. 119 The study, commis-
sioned by the FDA staff, declared that AHAs are safe at ten percent con-
centration and a pH of 3.5.120 The two key issues surrounding the study,
aside from actual effectiveness, was the risk of increased penetration of
the skin by other chemicals following AHA application and dermal irrita-
tion resulting from AHA use.121 The CIR Panel found that "there is no
need to be concerned about AHA ingredient use enhancing the penetra-
tion of other chemicals."' 122 With regard to dermal irritation caused by
AHAs, the Panel did find that "AHA ingredients can be dermal irritants,"
depending on the concentration and pH of the AHA formulations. 123 As
the Panel reported, "[a]t a given pH, increasing the concentration in-
creases irritation;"'124 furthermore, "[a]t a given concentration, reducing
the pH increases the irritation."'125 The Panel's primary concerns regard-
ing irritation focused on mid-range AHA formulations that are used by
salons. The Panel stated that AHAs used by salons are safe within the
following parameters and guidelines:
[A]t concentrations less than or equal to 30 percent, at
final formulation pH equal or greater than 3.0, in prod-
ucts designed for brief, discontinuous use followed by
thorough rinsing from the skin, when applied by trained
professionals, and when application is accompanied by
directions for the daily use of sun protection. 126
As far as cosmetic use (i.e., retail sale) is concerned, the CIR Panel
concluded that AHAs were safe at concentrations of up to ten percent
and at pH levels no lower than 3.5, provided that the particular AHA-
containing product was formulated to avoid increased sun sensitivity, or
contained instructions calling for the daily use of appropriate sun protec-
tion. 27 Despite the Panel's findings, however, the FDA has not formally
accepted the CIR study and will only consider it in relation to its own
Compendium. Industry uses the CIR's findings, but is not bound specifically to fol-
low them.
Greff, supra note 3, at 246.
119 See New Wrinkle On Age Creams, CONSUMER REP. ON HEALTH, Feb. 1997, at 22,
available in LEXIS, Health Library, Curnws File.
120 See Cynthia C. Urbano, CIR Declares Retail AHAs Safe at 10% Concentration and
3.5 pH Levels, CosM. & Ton.r-ams, at 11, available in LEXIS, Health Library, Curmws File.
121 See Kintish, supra note 103, at 26.
122 Id.
123 Id.
124 Id.
125 Id.
126 Id.
127 See id.
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internal evaluation. 128 In fact, the Panel's findings merely provide rec-
ommendations to the FDA that are in no way binding on the manufactur-
ers of AHAs. The controversy surrounding AHAs as cosmeceuticals has
obviously not been resolved.' 29
5. Renova
Renova, a Johnson & Johnson product, is the first drug to ever be
approved by the FDA for the treatment of fine wrinkles, 30 and the only
anti-aging cosmeceutical to undergo extensive, neutral, double-blind
studies producing results that parallel the manufacturer's claims.131 Re-
nova's active ingredient, tretinoin (a vitamin A derivative), is the same
ingredient used in Retin-A, the prescription acne treatment found to have
the side-effect of reducing fine wrinkles. 132 Tretinoin is a retinoid that
has demonstrated its ability to mitigate photoaged skin on Retin-A
users,133 although Retin-A's original function was to treat severe acne
and not photoaged skin.'34
Research demonstrates that Retinoids, as a whole, have a significant
physiological effect on the skin; in fact, "[n]o other known chemicals or
drugs can duplicate the diversity of anatomic and physiologic effects
brought about by retinoids."' 35 Renova is a 0.05% tretinoin emollient
cream that "uses a water-in-oil emulsion instead of the drying base used
in tretinoin (Retin-A).' 36 The result is that Renova is a milder (less
irritating on the skin) version of its sister product, Retin-A. The physio-
logical effect that Renova has on the skin is that it "sloughs off dead
surface cells, thickens the skin's living cells, and increases the produc-
tion of collagen-the spongy tissue that lies below the skin's epidermal
layer-making the skin more supple and less wrinlded."'137 In a large-
scale, six month, double-blind study, 0.05% tretinoin emollient cream
was shown to "reduce fine wrinkles and skin roughness, and it produced
histologic changes such as epidermal thickening, increased granular layer
128 See Donald A. Davis, Not Likely! Food and Drug Administration to Study Skin Care
Products Despite Industry's Findings, DRUG & COSM. I.nus., Feb. 1997, at 20, available in
LEXIS, Health Library, Cumws File.
129 During the spring of 1997, the National Toxicology Program of the National Institute
of Environmental Science accepted the FDA's proposal to study AHA safety. See Kurtzweil,
supra note 115. The institute's results are expected by the year 2000. See id.
130 See Renova, Man AD NEws, Feb. 1, 1996, at 32, available in 1996 WL 9195689.
131 See Gilchrest, supra note 117, at 867.
132 See Still Pushing Back the Boundaries of C&T, supra note 78.
133 See id.
134 See id,
135 Laura Newman, FDA Approves Tretinoin Emollient Cream; Tretinoin Becomes First
FDA-Approved Skin Cream for Treatment of Wrinkles, D M'AToLoolcA. Tmrms, Feb. 1, 1996,
at 1, available in 1996 WL 9079730.
136 Id.
137 Roach, supra note 106, at 94.
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thickness, stratum corneum compaction, and decreased melanin con-
tent."'138 The same study noted even greater benefits following twelve
months of use.
139
Renova is intended for mature dry skin as a nighttime facial cream
application that requires comprehensive sun protection during the period
of usage.' 40 Renova will not reverse the aging process, 14 1 although it has
been shown to improve the appearance of photoaged skin by improving
"roughness, fine wrinkling, irregular pigmentation, texture, and firm-
ness." 14 2 As with any use of a tretinoin-based topical product, Renova
does cause some skin irritation, especially during the first month of
use.143 While "the information for patients" labeling on Renova states
that "[a] majority of patients will lose most mitigating effects.., with
discontinuance,"'144 it has been asserted that the loss of such mitigating
effects is gradual.' 45 Renova users who fall within the narrow margin of
138 Barbara A. Gilchrest, Treatment of Photodamage With Topical Tretinoin: An Over-
view, 36 J. AM. AcAD. DERMATOLOGY 27 (1997).
139 See id.
140 See Newman, supra note 135, at 1.
141 Excluding the full one-sided magazine page devoted to listing indications and usage,
warnings, precautions, and adverse reactions, as required by the FDA for the advertisement of
an approved drug, Renova's advertisement in a popular woman's journal reads as follows:
Ask your dermatologist about Renova, from the makers of Retin-A. Renova
works. Renova is unlike any other anti-aging or anti-wrinkie cream. It is a prescrip-
tion cream that is proven to work. Because Renova is a prescription wrinkle cream,
you won't find it on any cosmetic shelf, you'll need to see your doctor. And while it
won't work overnight, if you follow a total skin care program, it can work for you.
How Renova and Retin-A are the same. And different. Renova is a rich emollient
cream whose active ingredient is a vitamin A derivative like the one naturally occur-
ring in your body. It's called Tretinoin. The same active ingredient in Retin-A. But
while Retin-A is formulated for acne-prone skin, Renova is a rich emollient cream
developed to treat lines, wrinkles, brown spots, and surface roughness. Leaving your
skin with a smoother texture and rosier glow. Renova works deep at the cellular
level to increase collagen. That's how researchers believe Renova reduces signs of
aging. Like other prescription medications, Renova has been tested for safety and
effectiveness. While it will not repair sun damaged skin or reverse the aging pro-
cess, it is proven to reduce wrinkles, fade brown spots, and smooth roughness.
When you use Renova, you can expect to experience some redness, itching, or flak-
ing. This is most often mild, and most common when treatment is started. Soon
your skin will become softer and smoother, with a rosier glow. When using Renova,
or any other anti-wrinkle cream, you should limit exposure to the sun and always use
a sunscreen. Renova is a dermal irritant. Results of use beyond 48 weeks have not
been established in controlled clinical trials. Some people using Renova longer have
shown evidence of atypical skin changes, the significance of which is unknown.
Clinical trials in those over 50 or with moderately or heavily pigmented skin have
not been conducted.
REDBoox, Apr. 1998, at 26.
142 Newman, supra note 135, at 1.
143 See id.
144 Id.
145 See id.
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candidates for beneficial use will usually notice a reduction in skin
roughness within the first month of usage, fading of skin discoloration
within six to eight weeks, and a diminishment of fine lines and wrinkles
within three to six months.146
Renova may appear to be a miracle remedy, but at least one study
has shown that similar results have been achieved through the ordinary
use of moisturizers. 147 However, irrespective of Renova's effectiveness
as compared to the effectiveness of ordinary retail cosmetic products,
Renova has survived rigorous testing in order to be approved as a drug
by the FDA, a process that no other retail anti-aging product has en-
dured.148 Although Johnson & Johnson's claims about the beneficial ef-
fects of Renova are significantly similar to those claims made by
manufacturers of retail AHA products, Renova users can feel confident
about the safety and efficacy of Renova, while AHA users can only hope
and assume that because AHAs are sold on the retail shelf and not by
prescription, they are safe and effective for cosmetic use based only upon
the particular manufacturers' claims. 149 Furthermore, consumers that are
aware of both the prescription product Renova and AHA-containing cos-
metic products may erroneously presume that Renova poses significantly
more risks simply because it is not available over-the-counter. This pre-
sumption, caused by the prescription/over-the-counter dichotomy, can
create consumer misconception about cosmeceuticals generally because
the FDA has yet to make clear bright-line rules regarding the avenue of
availability for such products. The result may be that consumers will not
treat retail cosmeceuticals with the same caution as they will prescription
cosmeceuticals.
6. Beta-Hydroxy Acids
Within the past year, beta hydroxy acids (BHAs) have leaped ahead
of AHAs as the hot new unregulated cosmeceutical for wrinkle reduc-
tion, with potential adverse economic and physical effects to the con-
sumer.'50 Typical of most cosmetics and cosmeceuticals, the published
efficacy research on BHAs (specifically, the effectiveness of salicylic
146 See Renova, supra note 130, at 32.
147 See Roach, supra note 106, at 94.
148 See id.
149 Note that the CIR study was only advisory in nature and not determinative of FDA
policy, and furthermore cannot attest to each individual manufacturer's AHA formulation,
based on concentration and pH. The study merely provided one resource from which to derive
information about efficacy and safety. Because the FDA has not regulated AHAs as drugs,
specific AHA formulations may not conspicuously fall within the parameters of what the CIR
study concluded as being safe.
150 See Skin Care & Color Cosmetics Annual Trend Report, DRUG & CosM. INDus., June
1, 1997, at 38, available in 1997 WL 9344538.
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acid for safely reducing wrinkles) is negligible at best.' 5 ' According to
one study, salicylic acid (the primary ingredient in all BHA formula-
tions) was more effective at just one-fifth the concentration of glycolic
acid (an AHA formulation ingredient), 152 with less potential for skin irri-
tation than that caused by glycolic acid.'5 3 Because BHAs are lipid solu-
ble, as opposed to water soluble like AHAs, BHAs concentrate their
exfoliation on the top layers of the skin as opposed to "localizing below
the surface, where irritation is likely to occur."' 54 It should be noted,
however, that there is dispute over the assertion that BHAs are less irri-
tating than AHAs. 55 Indeed, in 1995, Procter & Gamble had to suspend
worldwide sale of two of its BHA products (containing two-percent con-
centrations) following numerous complaints of blurred vision and watery
eyes. 156
Taking the lead in the new BHA trend, Oil of Olay, a Procter &
Gamble product, has introduced its Daily Renewal Cream, which con-
tains 1.5% salicylic acid in a moisturizing base, and is allegedly less
irritating and equally as effective as AHA formulations.' 5 7 Yet one of
the major marketing points manufacturers and industry-commissioned
dermatologists make about BHAs is that salicylic acid achieves deeper
penetration within the skin,58 and has the ability to "renew the stratum
comeum."' 159 It seems clear that if BHAs have, as claimed, the same, if
not a greater, beneficial effect than AHAs, 160 they too fall into the cos-
151 See infra notes 153-54.
152 See Alpha Hydroxy Acids in Cosmetics, supra note 105.
153 See Skin Care & Color Cosmetics Annual Trend Report, supra note 150, at 38.
154 Fighting Time: With Its Patented Beta Hydroxy Complex, Oil of Olay Age Defying
Series Dawns On A New Age In Skin Care, supra note 104, at 66.
155 See Faye Brookrnan, United States of Colour; Cosmetics, SOAP P FumERY & COSM.,
July 1997, at 17, available in LEXIS, Health Library, Curnws File.
156 See P&G Withdraws Skin Care Products, EuR. CosM. MARKETs, Apr. 1995, at IS,
available in LEXIS, Health Library, Allnws File.
157 See Symposium: Skin Disorders, supra note 114, at 115.
158 "SA provides more exfoliation and penetrates skin more effectively than GA. Oil of
Olay Age Defying Series, Almay Time-Off Revitalizer with a 16 percent concentration claim-
ing to deliver the benefits of hydroxy mini-peels formerly available only from dermatologists
and estheticians ." Skin Care & Color Cosmetics Annual Trend Report, supra note 150, at
38.
159 Fighting Time: With Its Patented Beta Hydroxy Complex, Oil of Olay Age Defying
Series Dawns On A New Age In Skin Care, supra note 104, at 66.
160 In comparing the effectiveness of AHAs versus BHAs, one non-peer-reviewed article
stated the following:
BHA, however, offers three advantages. It exfoliates not just on the surface but
also deeper into oil-clogged pores-something AHAs can't do. Two, it's less irritat-
ing (studies show that women report less redness, stinging, and burning using a BHA
vs. an AHA). Three, as a derivative of aspirin, it has a similar anti-inflammatory
effect on the skin. That is good news since many women with older, sundamaged
skin also suffer from tiny whiteheads that are a type of acne. BHA helps treat this
condition.
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meceutical category and should be considered a drug under FDA
guidelines.
Indeed, illustrating the consumer perception of drug-like effective-
ness of salicylic acid, a recent article in Cosmopolitan indicates that sali-
cylic acid, vitamin-A derivatives, 161 and AHAs are examples of the "new
miracle skin creams."' 162 This article highlights the popular perception
that the new anti-aging cosmetics are really products that have a drug-
like effect without the drug regulatory hassle, for reasons never ad-
dressed by any cosmetic advertisement or any commercial non-peer-re-
viewed article. Moreover, the language of the article implies that today's
new anti-aging cosmetics were given special FDA treatment. It quotes a
dermatologist who made the following statement: "They're packing their
products with effective ingredients-some formerly available only by
prescription."'163 However, once again, questionable claims, lack of effi-
cacy data, and no FDA regulation place the risk of economic and physi-
cal harm on the consumers-the parties least likely to be able to assess
the products' efficacy and safety.
Ill. A POLICY PROPOSAL
The current regulatory letter method for policing the cosmetics in-
dustry and its product claims has arguably been ineffective, since cos-
metics manufacturers continue to be more "daring" in their labeling and
advertisements. 164 Further, more sophisticated and questionable market-
ing methods continue to be developed. For example, uncited allusions to
"research" have become more common. Recent labeling and advertise-
ments have included the following:
clinical tests in an independent laboratory study [no cita-
tion] ... our research shows [no citation] ... a replica-
tion of the lipid group discovered by [manufacturer] to
be lacking in dry skin [no citation] ... long, proven track
record of renowned product research [no citation] ...
links natural extracts and enzyme technology to slow
down the loss of elasticity ... binds moisture into the
skin... fortifying nourishing creme... works below the
surface to encourage dry skin to react more like normal
Yun L. Wolfe, Smooth Away Wrinkles: New Way to Revitalize Older Skin, NaV=oN, Sept.
1997, at 47, available in LEXIS, Health Library, Cumws File.
161 Vitamin-A derivatives (e.g., retinols) are said to have a similar effect as tretinoin (i.e.,
they diminish wrinkles) without the irritation. See Skin Care & Color Cosmetics Annual
Trend Report, supra note 150, at 38.
162 Isabel Burton, The New Miracle Skin Creams, Cosmopo=WN, Oct 1997, at 184,
available in LEXIS, Health Library, Cumws File.
163 Id.
164 See infra note 165 and accompanying text.
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skin ... tautness is immediately reversed and suppleness
restored ... reduces signs of aging . . . "prescriptives"
[name of a cosmetic] ... "M.D. Formulations" [name of
a cosmetic] ... your skin ages more slowly... forever
young. 165
In addition, skin care cosmetics manufacturers have advertised us-
ing before and after pictures of skin, which are not actual results but are,
as indicated in small print, "photos [that] simulate clinical results. ' 166
Also, advertisements in newspapers simulating newspaper articles have
also been used. 167 Thus, claims by cosmetics manufacturers appear to
have become not only more "daring," but also more creative, signifi-
cantly broadening the gray area established over thirty years ago.
As evidenced by the scanty case law above, the standard for deter-
mining cosmetic-as-drug claims, when applied in litigation is not obvi-
ously clear and apparent, which is perhaps one reason why the FDA has
been slow to attack the numerous cosmeceuticals that patently appear to
qualify as violators of the Act. Further, as seen in Est'ee Lauder, the
more recent regulatory letter process is highly inefficient, and arguably
ineffective, when seen in light of more recent cosmetics claims. 168
Combining the current reality of the FDA's emphasis upon physical
safety and no clear regulation of cosmetic industry claims for its prod-
ucts, consumers, if knowledgeable about the FDA, can usually assume
165 VOGUE, January 1994, at 69; LES NOUVELLES EsTH QuEs, January 1994. Note that
some of the cosmetics labeling and advertisements that were deemed objectionable by the
FDA in its past regulatory letter efforts included: "anti-age... avoids formation of wrinkles"
[Regulatory Letter to Burton Wanetik, Skin Culture Institute, Inc., Ref: 34-NYK-89, 1989];
"reduc[es] the visible signs of aging" [Regulatory Letter to Robert Bocchi, Cosmetics Labora-
tories of America, Ref: LA-40-8, 1988]; "helps prevent the visible signs of aging" [Regulatory
Letter to Ronald Perelman, Revlon, Inc., Ref: 57-NYK-88, 1988]; "able to act directly on your
wrinkles and noticeably decrease their depth ... effectiveness... has been scientifically
measured to the accuracy of the micron... laboratory tests have proven their effectiveness ...
nourishes and smoothes the skin... [manufacturer] leads the world in applying the use of
plant extracts containing DNA for the benefit of beauty products ... proven results" [Regula-
tory Letter to Yves Rocher, Yves Rocher, Inc., Ref: 88-PHI-43, 1988]; "protects against cell
damage ... forms an invisible 'bulletproof vest' around cells... neutralizing renegade 'free
radicals' ... vastly increases cell renewal... proven to be a catalyst that helps correct [min-
eral] imbalance" [Letter to Stephen 'Strassler, Reviva Labs, Inc., Ref: 88-NWK-23, 1988].
Arguably, these claims are similar, if not identical, to those used today and may reflect the lack
of effectiveness of the current FDA policing methodology.
166 VOGUE, supra note 165, at 69 (emphasis added).
167 See Advertisement: Alpha Hydroxy, Anti-Aging Superstar: Yet Many Women Do Not
Really Know What It Is, or How It Works, WASHINGTON PosT, Jan. 5, 1994, at 4. The adver-
tisement has a dateline and uses a column format and font type identical to that of a newspaper
article. The advertisement speaks about an "alpha hydroxy acid" of which "[d]ermatologists
discovered an amazing new benefit.., to reduce the appearance of wrinkles... [and] con-
cluded that a substance could actually reverse the skin aging process." Id. No citation is
given.
168 See supra note 165.
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that cosmetic products are safe. 169 However, some cosmetic products,
such as aminophylline creams and various cosmeceuticals, conceal them-
selves within a yet unregulated gray area between drug and cosmetics-
an area that poses serious questions regarding safety.170 And even if
consumers may still have some degree of confidence in the FDA to mon-
itor the safety of cosmetics, they cannot have that same level of confi-
dence regarding the efficacy of these products. 171 Since the claims for
these products are not effectively limited to truthfulness by the FDA,
consumers base their purchase decisions on haphazard claim implications
rather than product quality or components. Indeed, it was the claim im-
plications that were seen in the Sudden Change, Line Away and Magic
Secret cases that determined liability even though all three products in
question were virtually identical in composition.' 72 Moreover, many
consumers are enticed to a greater degree by haphazard claims emphasiz-
ing hot new buzz words that label a particular product's formulation.
Phrases such as "alpha-hydroxy," "beta-hydroxy," and "enzyme technol-
ogy" all have a glamorizing effect on the consumer in that they label a
product's new "scientifically proven" formulation, but fail to accurately
convey the efficacy or safety of the product.
A primary purpose of the Act is economic protection. 173 As recog-
nized by the Sudden Change court, and through its analysis of its legisla-
tive history, the Act serves to "protect . . . the ultimate consumer's
economic interest."174 Furthermore:
169 However, even this assumption may not be true for all cosmetic products. In 1978, the
U.S. General Accounting Office reported that only about 40% of manufacturers and packers
had registered their plants under a voluntary industry program that is coordinated with the
FDA. See UNrn STATES GENERAL AccOUNTNG OFicE, CosMETIcs REGULATION: INFOR-
MATION ON VOLUNTARY AcTONs AGREED TO BY FDA AND Tm INDusTRY, GAOIHRD-90-58,
March 1990, at 2. Further, less than 20% of manufacturers, packers, and distributors had filed
ingredient listings, and, importantly, less than four percent had filed injury reports. See id. In
1989, with the exception of the ingredient listings, participation rates in the industry show a
decrease as compared with 1977. See id.
170 See supra notes 61 and 103 and accompanying text (discussing significant side
effects).
171 Compare prescription drugs, such as Renova, of which the consumer is usually as-
sured that there has been appropriate pre-clinical and clinical testing for safety and efficacy
before a new drug application is approved and the drug allowed onto the market. See supra
note 141, at 26.
172 The products' major ingredients were bovine albumin and distilled water. See United
States v. An Article... Consisting of 216 Individually Cartoned Bottles, More or Less, of an
Article Labeled In Part: Sudden Change, 288 F. Supp. 29 (E.D.N.Y. 1968), rev'd 409 F.2d
734, 736 (2d Cir. 1969); United States v. An Article of Drug Consisting of 36 Boxes, More or
Less, Each Containing One Bottle of an Article Labeled In Part "Line Away Temporary Wrin-
kle Smoother, Coty, 284 F. Supp. 107 (D.Del. 1968), affd, 415 F.2d 369, 372 (3d Cir. 1969);
United States v. An Article of Drug ... 47 Shipping Cartons, More or Less, ... "Helene Curtis
Magic Secret, 331 F. Supp. 912, 915 (D.Md. 1971).
173 See infra note 175.
174 Sudden Change, 409 F.2d at 740 (emphasis added); see also id. at 740 n.6.
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Economic harm is clearly an important consideration
and will, in some instances, justify court interven-
tion .... The agency must justify its delay to the court's
satisfaction.... [I]f an agency's failure to proceed expe-
ditiously will result in harm or substantial nullification
of a right conferred by statute, "the courts must act to
make certain that what can be done is done."'175
Thus, economic harm should be considered in determining the
FDA's discretion in avoiding active enforcement of section 602 of the
Act. Since this protection is mandated by the statute, and this right may
arguably be currently "nullified" by FDA inactivity, the FDA may be
abusing its discretion in its non-enforcement of the Act against cosmetics
manufacturers.
To protect these consumer interests, a favorable solution would use,
if possible, the current infrastructure and powers of the FDA and couple
them with more clear and effective standards for the cosmetics industry.
The use of the FDA rulemaking power may represent the optimal method
for more efficient and clear regulation in support of the FDA's enforce-
ment of the Act. 176
The FDA should construct a system under which it can effectively
monitor skin care cosmetics claims and also address the issue of how to
regulate cosmeceuticals. The fundamental regulatory tenet of this system
would be to require cosmetics manufacturers, when claims are identified
as they were at the outset of the regulatory letter process in the Est'ee
Lauder case, to provide clear, scientifically peer-reviewed research docu-
mentation supporting the efficacy claims of the cosmetic rather than tak-
ing the cosmetic-as-drug approach. 177 If the manufacturer could not
provide such evidence, the offending labeling could not be used and the
product would be deemed misbranded under section 602 of the Act. 178
An alternative would be to place the burden of regulatory compliance on
cosmetics manufacturers by requiring FDA approval of a product's effi-
cacy claims before allowing their use in labeling or advertisements. 17 9
Although the latter is preferable due to its preventive rather than correc-
tive nature, it also represents a more expensive, labor-intensive,
premarket approval-type approach that currently is used for prescription
175 Cutler v. Hayes, 818 F.2d 879, 898 (1987) (quoting American Broadcasting Company
v. Federal Communications Comm'n, 191 F.2d 492, 501 (1951)).
176 321 U.S.C. § 371(a) (1992).
177 See infra note 178.
178 Another alternative would be to have cosmetics manufacturers publish retractions of
efficacy claims as has been done with prescription drugs.
179 The Sudden Change court indicated that "there may be merit in the cause of those who
seek to require pretesting of new cosmetics," but declined to legislate such a requirement.
Sudden Change, 409 F.2d at 742.
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drugs. A policing emphasis may be less costly to the FDA while still
maintaining a great enough incentive for cosmetics manufacturers to use
nondeceptive claims. However, in order to maintain adequate incentives,
the probability of cosmetics manufacturers not being caught using unsub-
stantiated claims must be taken into account. Thus, if a manufacturer is
successful in avoiding FDA scrutiny fifty percent of the time, the relative
penalty must be twice that of a manufacturer who is caught 100% of the
time.180
Defining the relative evidence requirements would begin with a
rulemaking procedure,' 8 ' allowing the FDA, industry, consumers, and
other interested parties to participate in drafting the regulation. Ulti-
mately, perhaps one or two peer-reviewed, published studies would be
required in order to allow skin cosmetics claims to be used; in conjunc-
tion, or in the alternative, a third party, such as an independent labora-
tory, could be involved to assess the product and industry-submitted
data.'8 2 The standard would most likely be far lower than the double-
blind, clinical studies as required for new drug approval. The essential
component, however, would be that researchers, other than those with
the incentive to support cosmetics manufacturers' claims, have the op-
portunity to accept or reject the claims using established, neutral scien-
tific review. If the claims are substantiated, the FDA may then wish to
either require citation to that scientific article on the product's labeling or
create a symbol of claim approval to be affixed onto the cosmetic's label-
ing or advertisement. In either case, it should be clear to the consumer
when the FDA has approved the product's claims, and when it has not.183
180 See A. MrrciEu. POLINSKY, AN INTRODUCrION TO LAW AD ECONOMICs 78-86 (2d
ed. 1989).
181 The regulatory powers, including procedural regulations, for the FDA are derived
from 321 U.S.C. § 371 (1992). The rulemaking proceeding has had extensive support in the
courts:
[R]ule-making has been increasingly substituted for adjudication as a regulatory
technique, with the support and encouragement of the courts. The rule-making pro-
ceeding... provides the [FDA] with an opportunity first to receive a wide spectrum
of views proffered by all segments affected by the proposed rule... and then in a
legislative fashion to consider and choose from several alternatives. Furthermore,
once binding regulations are promulgated, the industry and public are put on notice
and may be guided accordingly rather than speculate as to the outcome of a seizure
or enforcement suit.
National Nutritional Foods Ass'n v. Weinberger, 512 F.2d 688, 698 (2d Cir. 1975).
182 Claim substantiation of skin care products by private organizations has been done in
the past. The National Advertising Division ("NAD") of the Council of Better Business Bu-
reaus investigated a skin care product that claimed to "accelerate the natural skin cell renewal
process" and "restore the skin's youthful ability to care for itself." McNamara, supra note 21,
at 158. The NAD found that the product's manufacturer was able to provide valid scientific
support for its claims. See id.
183 See also supra note 178 (noting retractions of wrongful claims may be beneficial to
provide consumers with appropriate information on efficacy).
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This proposal uses the current regulatory infrastructure to identify
questionable cosmetic claims. Thus, by using the already existing mech-
anism for identifying offending labeling and advertisement claims, the
new proposal has not created a fundamentally new bureaucracy. In addi-
tion, by putting the burden of proof on the industry and simply treating
the cosmetic as a cosmetic, the burden on the FDA to prove, if necessary
in court, that the cosmetic in question is a drug under the statutory defini-
tion, is obviated. Also, the extensive costs and wasted resources that
result from wrangling over advertisements and modifications thereof, as
was seen in the Est'ee Lauder case, are minimized.
Further, through use of the rulemaking procedure, a standard of evi-
dence with party input, and thus legitimacy, will be established that gives
relatively clear guidance by which cosmetics claims are to be scrutinized.
From the industry point of view, a standard that has been formulated
with its input will reduce the relative allocation of resources necessary
for negotiations with the FDA as to appropriate labeling standards, as
well as decrease the uncertainty as to the agency's relevant review meth-
ods. In addition, the honest competitor in the industry that is reluctant to
continually push the line of ethical marketing will be protected, and com-
petitors will compete on the basis of quality of the product, not on the
basis of unsubstantiated labeling or advertisements. 84
In a world of limited resources, sanctions should also be considered
from an efficiency and cost-effectiveness point of view. If a cosmetics
manufacturer has not corrected claims deemed inappropriate by the FDA,
informal mechanisms such as publicity (particularly general media such
as television), warning letters, voluntary detainment and voluntary recalls
should be attempted first. Only if these solutions are not effective should
the FDA exercise its formal, but expensive, powers of enforcement, in-
cluding seizure, injunction, and criminal prosecution. 185 By the use of
minimally expensive solutions with progressively more powerful, albeit
expensive, alternatives, FDA enforcement costs will be expended only to
the extent marginally necessary. 186
Finally, there are other policy rationales as to why cosmetic claims
require more effective policing. First, the very labeling and advertise-
ments that represent clearly questionable claims are subsidized by the
184 Shifting some of the approximately two billion dollars spent annually on cosmetics
advertising, see McNamara, supra note 21, at 157, to efficacy research and publication will
serve the consumer by resulting in more accurate labeling and advertising and a greater range
of efficacious products. Honest competitors will flourish due to competition based upon prod-
uct quality.
185 See also supra note 178.
186 The FDA may wish to consider requesting Congress to implement user fees for cos-
metics regulation similar to that for new prescription drugs. See Richard A. Merrill, The Ar-
chitecture of Government Regulation of Medical Products, 82 VA. L. Rnv. 1753, 1840 (1996).
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federal government. Advertisement and other business expenses are de-
ductible from corporate taxes under section 162 of the Internal Revenue
Code.187 Because of the implicit benefit given to cosmetics manufactur-
ers by the government for deduction of advertising and labeling costs, the
government in turn should demand a high quality of information from
manufacturers in their communications to consumers. The government
should not subsidize potential fraud. Second, from a statutory point of
view, nowhere in the Act is there allowance for cosmetics manufacturer
"puffery" by the FDA. If the product can substantiate safety and efficacy
claims, it is in compliance with the Act. On the other hand, if the prod-
uct is misbranded due to lack of efficacy, it is in violation of section 602
of the Act. The FDA (or the courts) should not be allowed to impose a
limitation on the protection of consumers that was not intended by Con-
gress through the Act itself. Finally, the use of scientific and medical
terminology in an inappropriate fashion, implying technical certainty
and/or testing to the unwary consumer, is an abuse of science and should
not be used to represent the imprimatur of the scientific or medical com-
munity on these products.
CONCLUSION
The practice of claiming questionable benefits for skin care cos-
metic products has continued and become more "daring" since the classic
cases of thirty years ago. The current FDA system of regulating ques-
tionable cosmetics claims through a cosmetic-as-drugs strategy, how-
ever, is inefficient for both the FDA and the cosmetics industry.
Furthermore, consumers, on the basis of past and current FDA actions,
cannot differentiate truthful and untruthful cosmetics claims.
In addition, beyond mere cosmetics, which pose only a risk of eco-
nomic loss, numerous cosmeceuticals being marketed as cosmetics also
have the potential for causing physical harm. Thus, not only is there a
need for the FDA to crack down on cosmetics manufacturers that are
marketing products that should be regulated as drugs under the Act, but
there is an even greater need for the FDA to utilize section 602 of the Act
to eliminate cosmetic advertisements that mislead consumers into believ-
ing a product is effective simply because non-cited claims say so. Con-
sumers are entitled to feel secure that they are fully informed as to the
safety and efficacy of the product they are buying. At the present time,
they have little foundation on which to base any such security.
By using the current FDA infrastructure to identify questionable
claims and also requiring scientific, peer-reviewed proof of safety and
187 Itemized Deductions for Individuals and Corporations: Trade or Business, I.R.C.
§ 162 (1993).
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efficacy for substantiation of these claims, the difficulties consumers face
with respect to both cosmetics and cosmeceuticals would be alleviated.
The standard of proof would be determined through a rulemaking pro-
cess so as to involve the FDA, industry, consumers, and other interested
parties. In this fashion, a legitimized standard would emerge for deter-
mining efficacy of skin care products. Sanctions would be also selected
on the basis of efficiency and would move progressively from informal
to formal measures, so as to utilize only the marginally necessary re-
sources for enforcement of the Act.
The cosmetics industry has come a long way in its attempts to de-
velop, market, and sell its products. The FDA, however, has not con-
comitantly evolved an efficient method of protecting the public's
economic and physical safety from questionable cosmetic products. By
requiring substantiation of cosmetics safety and efficacy claims, the in-
terests of the FDA, the honest cosmetics manufacturer, and the consumer
are jointly advanced.
